SLAMF7 and Miyoshi myopathy: Interestingly, elotuzumab and its F(ab’)2 fragment can stabilize the interaction between SLAMF7 on NK cells and MM cells and enhance MM cell killing, again suggesting the presence of elotuzumab-induced ADCC-independent cytotoxicity of NK cells against MM cells [16].